Abbott India Limited

ABBOTINDIA

INE358A01014

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 08:31:20 18/07/2024 BST			5-day change	1st Jan Change
28,700 ^INR	+0.34%		+3.15%	+25.59%

07-17	Abbott India Limited Announces Resignation of Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife, Effective October 16, 2024	CI
07-05	Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	RE

Abbott India Limited Announces Demise of its Independent Director, Ranjan Kapur

January 29, 2018 at 06:23 am

Abbott India Limited announced the sudden demise of Mr. Ranjan Kapur, Independent Director of the company on January 27, 2018. Mr. Kapur joined the board of the company in September 2006. He was also the Member/Chairman of the Audit, Nomination & Remuneration and CSR Committees of the company.

Latest news about Abbott India Limited

Abbott India Limited Announces Resignation of Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife, Effective October 16, 2024	07-17	CI
Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	07-05	RE
Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024	06-11	CI
Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3%	05-10	MT
Drugmaker Abbott India posts Q4 profit rise on higher sales	05-09	RE
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-09	CI
Abbott India Limited Recommends Final Dividend for the Year Ended March 31, 2024, Payable on or After August 13, 2024	05-09	CI
Abbott India Limited Appoints Murari Ranganathan as Commercial Director	04-12	CI
Abbott India's Managing Director Exits	03-19	MT
Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024	03-15	CI
Abbott India Names Managing Director	03-13	MT
GSK India arm's Q3 profit falls on government price cap	02-12	RE
Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-14	CI
Abbott India Managing Director to Step Down in March 2024	12-19	MT
Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
INDIA STOCKS-Indian shares set for muted opening; Delta Corp in focus after tax notice	25/09/23	RE
Abbott India warns of laxatives shortage in tussle with Goa regulator	22/09/23	RE
Goa state warns Abbott India on antacid license suspension	14/09/23	RE
Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023	09/08/23	CI
Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09/08/23	CI
Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023	24/07/23	CI
INDIA STOCKS-Indian shares recover from weak start on buying at key levels	22/05/23	RE
Abbott India Limited Approves the Appointment of Sridhar Kadangode as Chief Financial Officer, Effective July 1, 2023	19/05/23	CI
Abbott's India arm posts 9.5% rise in fourth-quarter profit	19/05/23	RE
Abbott India's Net Profit Climbs in Fiscal Q4	19/05/23	MT

Chart Abbott India Limited

Duration

Period

More charts

Company Profile

Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.

Sector

Pharmaceuticals

Calendar

18/07/2024 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBOTT INDIA LIMITED	+25.59%	7.27B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.56%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.06%	247B
NOVARTIS AG	+14.23%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals